Article Sidebar
Date Published:
11/12/2023
Abstract Views: 218
Views PDF: 141
Views PDF: 141
Issue
Section
Các bài báo
How to Cite
Nguyễn , H. ., Nguyễn , A. K. ., & Đỗ , Đức M. . (2023). GASTRIC CANCER WITH LIVER AND GREAT OMETUM METASTASES WERE TREATED BY GASTRECTOMY AND OMENTECTOMY WITH ADJUVANT CHEMOTHERAPY: A CASE REPORT AND LITERATURE. Vietnam Medical Journal, 532(2). https://doi.org/10.51298/vmj.v532i2.7531
GASTRIC CANCER WITH LIVER AND GREAT OMETUM METASTASES WERE TREATED BY GASTRECTOMY AND OMENTECTOMY WITH ADJUVANT CHEMOTHERAPY: A CASE REPORT AND LITERATURE
Main Article Content
Abstract
Stomach cancer ranks 5th in the worldwide of cancer(1), in which 90% of cancers develop from the mucosa layer of the stomach. Adjuvant chemotherapy is very important role in multimodality treatment to improve survival after surgery. However, the response to depends on the stage of the disease, the cell type, and the patient's tolerance. Through this, we would like to report clinically and review the literature of a case of gastric cancer that was operated on and responded well to chemotherapy with EOX regimen
Article Details
Keywords
Gastric cancer, EOX
References
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Sung - 2021 - CA: A Cancer Journal for Clinicians - Wiley Online Library [Internet]. [cited 2023 Jun 29]. Available from: https://acsjournals.onlinelibrary. wiley.com/doi/10.3322/caac.21660
2. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005 Jun 6;92(11):1976–83.
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205–16.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36–46.
5. Xiang XJ, Qiu F, Xiong JP, Zhang L, Yu F, Feng M, et al. A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience. Chemotherapy. 2010;56(3):171–7.
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Nov 1;24(31):4991–7.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215–21.
2. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005 Jun 6;92(11):1976–83.
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205–16.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36–46.
5. Xiang XJ, Qiu F, Xiong JP, Zhang L, Yu F, Feng M, et al. A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience. Chemotherapy. 2010;56(3):171–7.
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Nov 1;24(31):4991–7.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215–21.